Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers

CR Pickering, J Zhang, SY Yoo, L Bengtsson… - Cancer discovery, 2013 - AACR
CR Pickering, J Zhang, SY Yoo, L Bengtsson, S Moorthy, DM Neskey, M Zhao…
Cancer discovery, 2013AACR
The survival of patients with oral squamous cell carcinoma (OSCC) has not changed
significantly in several decades, leading clinicians and investigators to search for promising
molecular targets. To this end, we conducted comprehensive genomic analysis of gene
expression, copy number, methylation, and point mutations in OSCC. Integrated analysis
revealed more somatic events than previously reported, identifying four major driver
pathways (mitogenic signaling, Notch, cell cycle, and TP53) and two additional key genes …
Abstract
The survival of patients with oral squamous cell carcinoma (OSCC) has not changed significantly in several decades, leading clinicians and investigators to search for promising molecular targets. To this end, we conducted comprehensive genomic analysis of gene expression, copy number, methylation, and point mutations in OSCC. Integrated analysis revealed more somatic events than previously reported, identifying four major driver pathways (mitogenic signaling, Notch, cell cycle, and TP53) and two additional key genes (FAT1, CASP8). The Notch pathway was defective in 66% of patients, and in follow-up studies of mechanism, functional NOTCH1 signaling inhibited proliferation of OSCC cell lines. Frequent mutation of caspase-8 (CASP8) defines a new molecular subtype of OSCC with few copy number changes. Although genomic alterations are dominated by loss of tumor suppressor genes, 80% of patients harbored at least one genomic alteration in a targetable gene, suggesting that novel approaches to treatment may be possible for this debilitating subset of head and neck cancers.
Significance: This is the first integrated genomic analysis of OSCC. Only through integrated multiplatform analysis was it possible to identify four key pathways. We also discovered a new disease subtype associated with CASP8 and HRAS mutation. Finally, many candidate targetable events were found and provide hope for future genomically driven therapeutic strategies. Cancer Discov; 3(7); 770–81. ©2013 AACR.
See related commentary by Iglesias-Bartolome et al., p. 722
This article is highlighted in the In This Issue feature, p. 705
AACR